Solbec completes Phase I psoriasis trial
Wednesday, 09 February, 2005
Solbec Pharmaceuticals (ASX: SBP) has announced successful completion of its Phase I study of its devil's apple-derived drug Coramsine as a treatment for psoriasis.
Preliminary results from the trial, which incorporated two stages to look at the safety and tolerability in healthy individuals, plus a third stage to assess efficacy in ten patients with psoriasis, indicate that there were no treatment-related adverse events during the trial. The drug was administered in a cream formulation and in the efficacy stage of the trial, was compared to both placebo and to a standard treatment for psoriasis over a period of 56 days.
The company said efficacy results would be reported in the second quarter of this year, once the trial has been unblinded and data analysed.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
